{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:30:25Z","timestamp":1772641825540,"version":"3.50.1"},"reference-count":58,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Services, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>This retrospective chart review study investigated the clinical burden of adult patients with chronic-phase chronic myeloid leukemia (CP-CML) treated at three centers in France (2006\u20132021) who failed on two or more tyrosine kinase inhibitors (TKIs; third-line [3L]+ cohort) or harbored the BCR::ABL1 T315I mutation (T315I cohort). In the 3L+ cohort (N = 157; median age at diagnosis, 56 years), TKIs received in 3L (median duration: 17 months) were dasatinib (32%), nilotinib (19%), imatinib (18%), ponatinib (17%), and bosutinib (14%). Of the 145 patients with documented responses in 3L, 42% experienced major molecular response (MMR) at 12 months. Median event-free survival [95% confidence interval] was 53.6 [44.0, 67.5] months, and median progression-free survival and overall survival (OS) were not reached. Achieving MMR in 3L was associated with a decreased mortality risk. In the T315I cohort (N = 17; 52 years), 41% of patients received five or more lines of therapy. Following identification of the T315I mutation, ponatinib was the most common TKI used (59%); the median [interquartile range] OS was 5 [3\u201310] years. The most common adverse events were infections (3L+ cohort) and thrombocytopenia (T315I cohort) (both 18%). Well-tolerated therapies that achieve durable responses are needed in 3L or earlier to improve CP-CML prognosis.<\/jats:p>","DOI":"10.3390\/cancers15164161","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T09:13:44Z","timestamp":1692350024000},"page":"4161","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation"],"prefix":"10.3390","volume":"15","author":[{"given":"Franck-Emmanuel","family":"Nicolini","sequence":"first","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard, 69373 Lyon, France"},{"name":"Fi-LMC Group, 69437 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Huguet","sequence":"additional","affiliation":[{"name":"Fi-LMC Group, 69437 Lyon, France"},{"name":"H\u00e9matologie, Institut Universitaire du Cancer de Toulose\u2014Oncopole, 31100 Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA 02199, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Churong","family":"Xu","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Los Angeles, CA 90071, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Bouvier","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard, 69373 Lyon, France"},{"name":"Fi-LMC Group, 69437 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurore","family":"Yocolly","sequence":"additional","affiliation":[{"name":"Novartis Services, Inc., East Hanover, NJ 07936, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Etienne","sequence":"additional","affiliation":[{"name":"Fi-LMC Group, 69437 Lyon, France"},{"name":"Institut Bergoni\u00e9, 33076 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/leu.2016.246","article-title":"Treatment and outcome of 2904 CML patients from the EUTOS population-based registry","volume":"31","author":"Hoffmann","year":"2017","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1084\/jem.21210insight1","article-title":"Major progress in understanding progression in chronic myeloid leukemia","volume":"212","author":"Radich","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_3","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/GO.21.00194","article-title":"Magnitude and Temporal Trend of the Chronic Myeloid Leukemia: On the Basis of the Global Burden of Disease Study 2019","volume":"7","author":"Hu","year":"2021","journal-title":"JCO Glob. Oncol."},{"key":"ref_4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety","volume":"9","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_5","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: A systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv."},{"key":"ref_6","unstructured":"Glivec (Imatinib) (2022, November 22). Summary of Product Characteristics. European Medicines Agency. Updated on 5 April 2022. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/glivec."},{"key":"ref_7","unstructured":"Tasigna (Nilotinib) (2022, November 22). Summary of Product Characteristics. European Medicines Agency. Updated on 26 October 2022. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tasigna."},{"key":"ref_8","unstructured":"Sprycel (Dasatinib) (2022, November 22). Summary of Product Characteristics. European Medicines Agency. Updated on 17 June 2022. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sprycel."},{"key":"ref_9","unstructured":"Bosulif (Bosutinib) (2022, November 22). Summary of Product Characteristics. European Medicines Agency. Updated on 9 June 2022. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bosulif."},{"key":"ref_10","unstructured":"Iclusig (Ponatinib) (2022, November 22). Summary of Product Characteristics. European Medicines Agency. Updated on 21 October 2022. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/iclusig."},{"key":"ref_11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/ejh.13524","article-title":"Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data","volume":"106","author":"Chen","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ajh.25306","article-title":"Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY","volume":"94","author":"Hehlmann","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: First-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Breccia, M., Chiodi, F., Nardozza, A.P., Valsecchi, D., Perrone, V., Sangiorgi, D., Giacomini, E., Rendace, M.C., Coco, P., and Premoli, E. (2022). Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133597"},{"key":"ref_15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/01.HS9.0000843528.26169.66","article-title":"Qu\u00e9bec CML Research Group analysis of treatment patterns in chronic myelogenous leukemia: Switching is driven by intolerance and similar across tyrosine kinase inhibitors and lines of treatment (S159)","volume":"6","author":"Busque","year":"2022","journal-title":"HemaSphere"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kong, J.H., Winton, E.F., Heffner, L.T., Gaddh, M., Hill, B., Neely, J., Hatcher, A., Joseph, M., Arellano, M., and El-Rassi, F. (2020). Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051542"},{"key":"ref_17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.16733","article-title":"Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: The UK TARGET CML study","volume":"192","author":"Milojkovic","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000524284","article-title":"Incidence, Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data Analysis","volume":"45","author":"Kohlbrenner","year":"2022","journal-title":"Oncol. Res. Treat."},{"key":"ref_19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.3324\/haematol.2019.240739","article-title":"Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?","volume":"105","author":"Branford","year":"2020","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1185\/03007995.2015.1120189","article-title":"Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia","volume":"32","author":"McGarry","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_23","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1182\/blood-2010-06-291922","article-title":"Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy","volume":"116","author":"Ibrahim","year":"2010","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_27","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3109\/10428194.2014.974046","article-title":"Incidence of chronic myeloid leukemia and patient survival: Results of five French population-based cancer registries 1980\u20132009","volume":"56","author":"Penot","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjh.16145","article-title":"Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: A prospective observational study in daily clinical practice","volume":"187","author":"Huguet","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2020-137393","article-title":"Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: Current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_31","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1182\/blood-2021-148773","article-title":"Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence","volume":"138","author":"Dahlen","year":"2021","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1182\/blood.V126.23.4025.4025","article-title":"Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial","volume":"126","author":"Hochhaus","year":"2015","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1182\/blood.V118.21.1691.1691","article-title":"Shorter Time to Achieve a Major Molecular Response (MMR) Is Predictive of a Faster Complete Molecular Response in CML: A Study of Characteristics and Outcomes of a Cohort of CML Patients in MMR","volume":"118","author":"Michallet","year":"2011","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3109\/10428194.2013.772607","article-title":"Surrogate end points for long-term outcomes in chronic myeloid leukemia","volume":"54","author":"Akwaa","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jval.2013.07.004","article-title":"Complete Cytogenetic Response and Major Molecular Response as Surrogate Outcomes for Overall Survival in First-Line Treatment of Chronic Myelogenous Leukemia: A Case Study for Technology Appraisal on the Basis of Surrogate Outcomes Evidence","volume":"16","author":"Oriana","year":"2013","journal-title":"Value Health"},{"key":"ref_37","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/ajh.24536","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s11136-021-02794-5","article-title":"Health state utility and quality of life measures in patients with chronic myeloid leukemia in France","volume":"30","author":"Foulon","year":"2021","journal-title":"Qual. Life Res."},{"key":"ref_39","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv."},{"key":"ref_40","doi-asserted-by":"publisher","first-page":"675811","DOI":"10.3389\/fphys.2021.675811","article-title":"Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review","volume":"12","author":"Santoro","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_41","unstructured":"(2022, December 15). Treatment with Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-Generation TKIs. ClinicalTrials.gov Identifier: NCT05311943. Updated 29 July 2022, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05311943."},{"key":"ref_42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2020-142142","article-title":"Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"ref_43","unstructured":"(2022, December 15). Safety and Anti-Leukemic Activity of Vodobatinib (K0706) for Treatment Refractory\/Intolerant CML Failing \u22653 Prior CML Therapies. ClinicalTrials.gov Identifier: NCT02629692. Updated 8 December 2022, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02629692."},{"key":"ref_44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1182\/blood-2020-139847","article-title":"Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"key":"ref_45","unstructured":"(2022, December 15). Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults with Ph+ Chronic Myeloid Leukemia, which Is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene. ClinicalTrials.gov Identifier: NCT02885766. Updated 17 February 2020, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02885766."},{"key":"ref_46","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1182\/blood-2019-127951","article-title":"PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I","volume":"134","author":"Turkina","year":"2019","journal-title":"Blood"},{"key":"ref_47","unstructured":"Scemblix (Asciminib) (2022, December 06). Summary of Product Characteristics. European Medicines Agency. Updated on 7 September 2022. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/scemblix."},{"key":"ref_48","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Mauro","year":"2021","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1200\/JCO.2022.40.16_suppl.7004","article-title":"Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after\u2265 2 prior tyrosine kinase inhibitors (TKIs): Week 96 update","volume":"40","author":"Rea","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41408-021-00420-8","article-title":"Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice","volume":"11","author":"Luna","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_51","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/01.HS9.0000845708.96602.91","article-title":"Asciminib use in CML: The UK experience. P706","volume":"6","author":"Innes","year":"2022","journal-title":"Hemasphere"},{"key":"ref_52","doi-asserted-by":"publisher","first-page":"9654","DOI":"10.1182\/blood-2022-162268","article-title":"Two-Year Updated Results of Asciminib Managed-Access Program (MAP) in Russia","volume":"140","author":"Turkina","year":"2022","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.1182\/blood-2022-163221","article-title":"Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia","volume":"140","author":"Chee","year":"2022","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1182\/blood-2022-167453","article-title":"Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors","volume":"140","author":"Luna","year":"2022","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","article-title":"The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis","volume":"98","author":"Nicolini","year":"2013","journal-title":"Haematologica"},{"key":"ref_57","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(\u03d5)-LMC GROUP)","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/16\/4161\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:36:26Z","timestamp":1760128586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/16\/4161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":58,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15164161"],"URL":"https:\/\/doi.org\/10.3390\/cancers15164161","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]}}}